Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.60 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.60 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.60 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.56 |
| ▸ | CPB1 | P15086 | 1/20 | 0.55 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.55 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29072142 | 0.96 | CA1 (0.64) | CA1CA2SIRT2SIRT1SIRT3 | |
| SCHEMBL29072091 | 0.96 | CA1 (0.64) | CA1CA2SIRT2SIRT1SIRT3 | |
| SCHEMBL29326174 | 0.92 | FOLH1 (0.70) | SIRT2SIRT1FOLH1HTTPTGER4 | |
| SCHEMBL29727761 | 0.92 | FOLH1 (0.70) | SIRT2SIRT1FOLH1HTTPTGER4 | |
| SCHEMBL14157704 | 0.91 | SIRT2 (0.67) | CA1CA2SIRT2SIRT1SIRT3 | |
| SCHEMBL14157706 | 0.91 | SIRT2 (0.67) | CA1CA2SIRT2SIRT1SIRT3 | |
| SCHEMBL18907026 | 0.91 | SIRT2 (0.67) | CA1CA2SIRT2SIRT1SIRT3 | |
| SCHEMBL17435163 | 0.91 | SIRT2 (0.67) | CA1CA2SIRT2SIRT1SIRT3 | |
| SCHEMBL29727709 | 0.90 | KLK7 (0.57) | SIRT2FOLH1HTTPTGER4CPB1 | |
| SCHEMBL21018995 | 0.88 | SIRT2 (0.62) | CA1CA2SIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| EP-4274582-A1 | HYPOIMMUNOGENIC BIOTHERAPEUTICS | Osprey Biopharmaceuticals, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2022150726-A1 | HYPOIMMUNOGENIC BIOTHERAPEUTICS | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | FCGR3B, CD47, IL2 | CA1 4539/4885CA2 4456/4885SIRT2 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.